I. Dybedal

发表

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

L. Möllgård, L. Saft, M. Treppendahl, 2011, Haematologica.

Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders

Ivan K. Chinn, Eric A. Smith, J. Lupski, 2017, The Journal of allergy and clinical immunology.

Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

S. Mustjoki, I. Dybedal, P. Kovanen, 2008 .

Phenotype, penetrance, and treatment of 133 cytotoxic T‐lymphocyte antigen 4–insufficient subjects

O. Elemento, T. Giese, A. Schulz, 2018, The Journal of allergy and clinical immunology.

Germline predisposition to myeloid neoplasms Recommendations for genetic diagnosis, clinical management and follow-up Nordic guidelines

I. Dybedal, K. Grønbæk, A. Stray-Pedersen, 2019 .

C0380: Clinical and Biochemical Consequences of Met1Ileu Mutation in Serpinc1 Gene: Generation of a Small Non-Inhibitory Antithrombin Variant without the N-Terminal Region by Use of an Alternative Initiation Codon that Has a Strong Gain-Of-Function Associated WI

K. Heimdal, I. Dybedal, F. Corrales, 2014 .

University of Southern Denmark Multidisciplinary Management of Mastocytosis

B. Sander, G. Nilsson, C. Bindslev‐Jensen, 2016 .

Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus.

B. Sander, G. Nilsson, C. Bindslev‐Jensen, 2016, Acta dermato-venereologica.

Multidisciplinary Management of Mastocytosis Broesby-Olsen , Sigurd 2016-07

B. Sander, G. Nilsson, C. Bindslev‐Jensen, 2022 .

Human reconstituting hematopoietic stem cells up-regulate Fas expression upon active cell cycling but remain resistant to Fas-induced suppression.

S. E. Jacobsen, I. Dybedal, Liping Yang, 2003, Blood.

Transforming growth factor-beta1 abrogates Fas-induced growth suppression and apoptosis of murine bone marrow progenitor cells.

I. Dybedal, S. Jacobsen, S. Nagata, 1997, Blood.

Repopulating Human Hemopoietic Stem Negatively Modulates Self-Renewal of γ IFN -

I. Dybedal, L. Nilsson, Y. Sasaki, 2004 .

Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: Clinical and molecular genetic prognostic factors in a Nordic population.

J. W. Hansen, E. Papaemmanuil, I. Dybedal, 2021, Transplantation and cellular therapy.

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.

I. Dybedal, O. Linder, L. Kanter‐Lewensohn, 1998, Blood.

A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes.

I. Dybedal, E. Hellström-Lindberg, G. Birgegard, 1993, Leukemia & lymphoma.

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

I. Dybedal, M. Jädersten, E. Hellström-Lindberg, 2005, Blood.

The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial

I. Dybedal, K. Warnatz, B. Grimbacher, 2022, Contemporary clinical trials communications.

Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need.

M. Cazzola, C. Pascutto, I. Dybedal, 2006 .

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Commentary

I. Dybedal, M. Jädersten, P. Fenaux, 2005 .

No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease

G. Gahrton, I. Dybedal, O. Linder, 2003, Leukemia.

Randomized Phase II Study and Long-Term Follow-Up of 71 Patients Colony-Stimulating Factor Plus Erythropoietin: Results From a Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte

I. Dybedal, O. Linder, L. Kanter‐Lewensohn, 2009 .

Treatment of myelodysplastic syndromes with retinoic acid and 1α‐hydroxy‐vitamin D3 in combination with low‐dose ara‐C is not superior to ara‐C alone. Results from a randomized study

E. Kimby, I. Dybedal, A. Öst, 1990 .

Transforming growth factor beta (TGF-beta), a potent inhibitor of erythropoiesis: neutralizing TGF-beta antibodies show erythropoietin as a potent stimulator of murine burst-forming unit erythroid colony formation in the absence of a burst-promoting activity.

I. Dybedal, S. Jacobsen, S. Jacobsen, 1995, Blood.

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

S. Mustjoki, M. Höglund, I. Dybedal, 2008, Leukemia.

A man in his seventies with back pain, gastrointestinal symptoms and rash.

I. Dybedal, H. Reikvam, N. Vetti, 2019, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

cells signaling growth inhibition of human CD34+ erythroid progenitor The RAR-RXR as well as the RXR-RXR pathway is involved in

E. Smeland, I. Dybedal, S. Jacobsen, 2013 .

The RAR-RXR as well as the RXR-RXR pathway is involved in signaling growth inhibition of human CD34+ erythroid progenitor cells.

E. Smeland, I. Dybedal, S. Jacobsen, 1996, Blood.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

J. Panse, I. Dybedal, M. Deininger, 2021, Nature Medicine.

IL-12 directly enhances in vitro murine erythropoiesis in combination with IL-4 and stem cell factor.

I. Dybedal, S. Jacobsen, S. Larsen, 1995, Journal of immunology.

Therapeutic options for CTLA-4 Insufficiency.

V. Lougaris, T. Morio, K. Sullivan, 2021, The Journal of allergy and clinical immunology.

The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors

I. Dybedal, M. Remberger, G. Tjønnfjord, 2020, Clinical hematology international.

IFN-γ Negatively Modulates Self-Renewal of Repopulating Human Hemopoietic Stem Cells1

S. E. Jacobsen, I. Dybedal, L. Nilsson, 2005, The Journal of Immunology.

Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with streptococcus viridans.

I. Dybedal, J. Lamvik, 1989, European journal of haematology.

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.

M. Cazzola, C. Pascutto, I. Dybedal, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up

O. Kilpivaara, I. Dybedal, K. Grønbæk, 2019, HemaSphere.

Transforming Growth Factor-β1 Abrogates Fas-Induced Growth Suppression and Apoptosis of Murine Bone Marrow Progenitor Cells

I. Dybedal, S. Jacobsen, S. Nagata, 1997 .

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

S. Linnarsson, R. Sandberg, P. Campbell, 2014, Cancer cell.

Self-Renewal of Multipotent Long-Term Repopulating Hematopoietic Stem Cells Is Negatively Regulated by FAS and Tumor Necrosis Factor Receptor Activation

I. Dybedal, J. Adolfsson, D. Bryder, 2001, The Journal of experimental medicine.

Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells.

I. Dybedal, S. Jacobsen, D. Bryder, 2001, Blood.

HLA-DPB1 mismatch reduce relapse and improve survival in T-cell replete unrelated donor allogeneic stem cell transplantation

I. Dybedal, M. Remberger, G. Tjønnfjord, 2020, Bone Marrow Transplantation.

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life

I. Dybedal, O. Linder, L. Kanter‐Lewensohn, 2003, British journal of haematology.

Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells

I. Mills, R. Lyle, I. Dybedal, 2016, Epigenetics & Chromatin.

Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation

H. Holte, T. Egeland, I. Dybedal, 2012, Bone Marrow Transplantation.

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

U. Olsson‐Strömberg, S. Mustjoki, T. Fioretos, 2013, Leukemia.

Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report

I. Dybedal, U. Randen, G. Tjønnfjord, 2018, Journal of Medical Case Reports.

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis

J. Panse, I. Dybedal, M. Deininger, 2022, Blood advances.

Avapritinib versus Placebo in Indolent Systemic Mastocytosis.

M. Triggiani, I. Dybedal, T. Tashi, 2023, NEJM evidence.

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation

I. Dybedal, E. Ejerblad, M. Jädersten, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.